论文部分内容阅读
目的观察非小细胞肺癌(NSCLC)外科根治术后辅助紫杉醇脂质体、卡铂化疗疗效及其毒副反应。方法20例NSCLC外科根治术后,采用紫杉醇脂质体、卡铂辅助化疗(辅助化疗组);同期25例NSCLC单纯行手术根治,而未行化疗(单纯手术组)。观察两组患者短期生存率和化疗的毒副反应。结果辅助化疗组和单纯手术组的1年半生存率分别为85.0%和72.0%,差异无统计学意义。化疗毒副反应主要为骨髓抑制和胃肠道反应,神经毒性低。结论NSCLC根治术后辅助紫杉醇脂质体联合卡铂方案化疗毒副反应较轻,比较安全。
Objective To observe the efficacy and toxicity of adjuvant paclitaxel liposomes and carboplatin after radical surgery for non-small cell lung cancer (NSCLC). Methods Twenty cases of NSCLC after radical surgery were treated with paclitaxel liposome and carboplatin adjuvant chemotherapy (adjuvant chemotherapy). In the same period, 25 cases of NSCLC were treated by radical surgery alone without chemotherapy. Short-term survival and chemotherapy side effects were observed in both groups. Results The one-year and one-year survival rates of the adjuvant chemotherapy group and the surgery alone group were 85.0% and 72.0%, respectively, with no significant difference. Chemotherapy toxicity mainly for bone marrow suppression and gastrointestinal reactions, low neurotoxicity. Conclusion Adjuvant chemotherapy with paclitaxel liposome plus carboplatin after radical operation of NSCLC is mild and safe.